パミドロン酸

関: pamidronate、pamidronate disodium

WordNet

street name for lysergic acid diethylamide (同)back breaker, battery-acid, dose, dot, Elvis, loony toons, Lucy in the sky with diamonds, pane, superman, window pane, Zen
any of various water-soluble compounds having a sour taste and capable of turning litmus red and reacting with a base to form a salt
having the characteristics of an acid; "an acid reaction"

PrepTutorEJDIC

酸性の / 酸味のある,すっぱい(sour) / (言葉・態度などが)厳しい,しんらつな / 酸 / すっぱいもの / 《俗》=LSD

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/06/25 16:50:12」(JST)

wiki en

[Wiki en表示]

Pamidronic acid (INN) or pamidronate disodium (USAN), pamidronate disodium pentahydrate is a nitrogen-containing bisphosphonate, used to prevent osteoporosis. It is marketed by Novartis under the brand name Aredia. In India, it is marketed by Curacell Biotech under the brand name Pamimed.

Uses

It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. In multiple myeloma, it is usually administered as an intravenous infusion, lasting about 3 hours. The therapy is repeated monthly, and lasts for the life of the patient. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels. It is also used as an experimental treatment of the bone disorder known as Osteogenesis Imperfecta. It has been studied in the treatment of Complex Regional Pain Syndrome.^[1]

Administration

Intravenous, usually 90 mg monthly. 30 mg, 60 mg, 90 mg and for hospitals, 120 mg vials are available, mixed with mannitol.

Side effects

Common side effects include bone pain, low calcium levels, nausea, and dizziness. Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.^[2]

Pamidronate activates human γδ T cells in vitro and in vivo, which may lead to flu-like symptoms upon administration.

References

^ Kubalek, O. Fain, J. Paries, A. Kettaneh, M. Thomas (2001). "Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases.". Rheumatology 40 (12): 1394–1397. doi:10.1093/rheumatology/40.12.1394. PMID 11752511.
^ Zarychanski R, Elphee E, Walton P, Johnston J (2006). "Osteonecrosis of the jaw associated with pamidronate therapy.". Am J Hematol 81 (1): 73–5. doi:10.1002/ajh.20481. PMID 16369966.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 高カルシウム血症の治療 treatment of hypercalcemia
2. 多発性骨髄腫患者のビスフォスフォネート製剤の使用 the use of bisphosphonates in patients with multiple myeloma
3. 骨形成不全症：管理および予後 osteogenesis imperfecta management and prognosis
4. 閉経後女性における骨粗鬆症に対するビスホスホネート投与 the use of bisphosphonates in postmenopausal women with osteoporosis
5. 進行癌患者における骨吸収抑制薬による薬剤療法のリスク risks of therapy with bone antiresorptive agents in patients with advanced malignancy

English Journal

Immobilization of pamidronic acids on the nanotube surface of titanium discs and their interaction with bone cells.

Koo TH1, Borah JS, Xing ZC, Moon SM, Jeong Y, Kang IK.Author information 1Department of Polymer Science and Engineering, Kyungpook National University, Daegu, 702-701, South Korea. ikkang@knu.ac.kr.AbstractSelf-assembled layers of vertically aligned titanium nanotubes were fabricated on a Ti disc by anodization. Pamidronic acids (PDAs) were then immobilized on the nanotube surface to improve osseointegration. Wide-angle X-ray diffraction, X-ray photoelectron microscopy, and scanning electron microscopy were employed to characterize the structure and morphology of the PDA-immobilized TiO2 nanotubes. The in vitro behavior of osteoblast and osteoclast cells cultured on an unmodified and surface-modified Ti disc was examined in terms of cell adhesion, proliferation, and differentiation. Osteoblast adhesion, proliferation, and differentiation were improved substantially by the topography of the TiO2 nanotubes, producing an interlocked cell structure. PDA immobilized on the TiO2 nanotube surface suppressed the viability of the osteoclasts and reduced their bone resorption activity.
Nanoscale research letters.Nanoscale Res Lett.2013 Mar 12;8(1):124. doi: 10.1186/1556-276X-8-124.
Self-assembled layers of vertically aligned titanium nanotubes were fabricated on a Ti disc by anodization. Pamidronic acids (PDAs) were then immobilized on the nanotube surface to improve osseointegration. Wide-angle X-ray diffraction, X-ray photoelectron microscopy, and scanning electron microscop
PMID 23497321

Denosumab and bone metastases. No better than a bisphosphonate.

[No authors listed]AbstractThe standard treatment used to prevent clinical repercussions of bone metastases from solid tumours consists of an intravenous bisphosphonate such as pamidronic acid. Denosumab,a monoclonal antibody injected subcutaneously, has been licensed in the European Union for use in this setting. Three double-blind randomised trials including a total of about 6000 patients showed no tangible difference between denosumab and zoledronic acid in terms of mortality, disease progression, quality of life, or pain. The authors resorted to a composite endpoint in order to demonstrate a statistically significant difference in favour of denosumab. Overall, toxicity was similar with denosumab and zoledronic acid in the 3 trials. Adverse effects that were more frequent with denosumab than with zoledronic acid included jaw osteonecrosis (1.8% versus 1.3%) and hypocalcaemia (9.3% versus 4.7%). However, renal failure was less frequent (2.6% versus 3.7%). Denosumab is administered subcutaneously and zoledronic acid by intravenous infusion. It is not known whether local and systemic reactions to administration are different. In practice, there is no tangible reason to choose denosumab rather than a bisphosphonate.
Prescrire international.Prescrire Int.2012 Sep;21(130):204-6.
The standard treatment used to prevent clinical repercussions of bone metastases from solid tumours consists of an intravenous bisphosphonate such as pamidronic acid. Denosumab,a monoclonal antibody injected subcutaneously, has been licensed in the European Union for use in this setting. Three doubl
PMID 23016249

Pamidronic acid and cabergoline as effective long-term therapy in a 12-year-old girl with extended facial polyostotic fibrous dysplasia, prolactinoma and acromegaly in McCune-Albright syndrome: a case report.

Classen CF1, Mix M, Kyank U, Hauenstein C, Haffner D.Author information 1University Children's Hospital, Ernst-Heydemann-Strasse 8, D-18057 Rostock, Germany. cfclassen@gmx.de.AbstractINTRODUCTION: McCune-Albright syndrome is a complex inborn disorder due to early embryonal postzygotic somatic activating mutations in the GNAS1 gene. The phenotype is very heterogeneous and includes polyostotic fibrous dysplasia, typically involving the facial skull, numerous café-au-lait spots and autonomous hyperfunctions of several endocrine systems, leading to hyperthyroidism, hypercortisolism, precocious puberty and acromegaly.
Journal of medical case reports.J Med Case Rep.2012 Jan 24;6:32. doi: 10.1186/1752-1947-6-32.
INTRODUCTION: McCune-Albright syndrome is a complex inborn disorder due to early embryonal postzygotic somatic activating mutations in the GNAS1 gene. The phenotype is very heterogeneous and includes polyostotic fibrous dysplasia, typically involving the facial skull, numerous café-au-lait spots an
PMID 22273876

Related Pictures

★リンクテーブル★

リンク元

「パミドロン酸」

Pamidronic acid
Systematic (IUPAC) name
	(3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid)
Clinical data
AHFS/Drugs.com	International Drug Names
MedlinePlus	a601163
Pregnancy; category	AU: B3; US: D (Evidence of risk);
Legal status	UK: Prescription-only (POM); US: ℞-only;
Routes of; administration	Intravenous
Pharmacokinetic data
Bioavailability	n/a
Protein binding	54%
Metabolism	Nil
Biological half-life	28 ± 7 hours
Excretion	Renal
Identifiers
CAS Registry Number	40391-99-9
ATC code	M05BA03
PubChem	CID: 4674
IUPHAR/BPS	7259
DrugBank	DB00282
ChemSpider	4512
UNII	OYY3447OMC
KEGG	D07281
ChEMBL	CHEMBL834
Chemical data
Formula	C3H11NO7P2
Molecular mass	235.07 g/mol
	SMILES O=P(O)(O)C(O)(CCN)P(=O)(O)O;
	InChI InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11) ; Key:WRUUGTRCQOWXEG-UHFFFAOYSA-N ;
(what is this?) (verify)

　　[★]

英: pamidronate、pamidronic acid
同: パミドロネート、パミドロン酸二ナトリウム pamidronate disodium
商: アレディア Aredia

他に分類されない代謝性医薬品

[Kubalek-1] Kubalek, O. Fain, J. Paries, A. Kettaneh, M. Thomas (2001). "Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases.". Rheumatology 40 (12): 1394–1397. doi:10.1093/rheumatology/40.12.1394. PMID 11752511.

[Zarychanski-2] Zarychanski R, Elphee E, Walton P, Johnston J (2006). "Osteonecrosis of the jaw associated with pamidronate therapy.". Am J Hematol 81 (1): 73–5. doi:10.1002/ajh.20481. PMID 16369966.

匿名

検索

案内

案内

pamidronic acid